Skip to main content

Table 4 Positive rates of serum SV2A in cases negative for other biomarkers

From: Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease

 

aMCI

AD

SV2A (+) / NfL (−)

100.00% (24/24)

75% (54/72)

SV2A (+) / GFAP (−)

92.86% (13/14)

72.50% (29/40)

SV2A (+) / p-tau217 (−)

97.06% (33/34)

79.25% (42/53)

  1. Abbreviations: AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; GFAP(−), serum GFAP-negative patients (≤ 7.67 pg/mL in aMCI, ≤ 12.93 pg/mL in AD); GFAP, glial fibrillary acidic protein; NfL(−), serum NfL-negative patients (≤ 9.68 pg/mL in aMCI, ≤ 15.53 pg/mL in AD); NfL, neurofilament light; p-tau217(−), serum p-tau217-negative patients (≤ 3.24 pg/mL in aMCI, ≤ 3.09 pg/mL in AD); p-tau217, phosphorylated tau; SV2A (+), serum SV2A-positive patients (≤ 5050.24 pg/mL in aMCI, ≤ 1674.02 pg/mL in AD); SV2A, synaptic vesicle glycoprotein 2 A
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193